Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À¯¹æ¾Ï¿¡¼­ Nitric Oxide SynthaseÀÇ ¹ßÇö Nitric Oxide Synthase (NOS) Expression in Breast Cancer

´ëÇÑ¿Ü°úÇÐȸÁö 2002³â 63±Ç 2È£ p.105 ~ 111
ÀÌÇØ°æ, Á¶¹éÇö, Çã¹ÎÈñ, °­¼º¼ö, ÀÌÁöÇö, À̼º°ø, ±èÇýÁ¤, ±èÀÇÁ¤, ¹®º´»ê, ±è¼¼Áß, ÇÑÇý½Â, ÁÖ¿µÃ¤, ½Å¼®È¯,
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌÇØ°æ ( Lee Hae-Kyung ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼ºÁ¦ÀϺ´¿ø ÀϹݿܰú

Á¶¹éÇö ( Cho Back-Hyun ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼ºÁ¦ÀϺ´¿ø ¿Ü°ú
Çã¹ÎÈñ ( Hur Min-Hee ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼ºÁ¦ÀϺ´¿ø ÀϹݿܰú
°­¼º¼ö ( Kang Sung-Soo ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼ºÁ¦ÀϺ´¿ø ¿Ü°ú
ÀÌÁöÇö ( Lee Jee-Hyun ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼ºÁ¦ÀϺ´¿ø ¿Ü°ú
À̼º°ø ( Lee Sung-Kong ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼ºÁ¦ÀϺ´¿ø ¿Ü°ú
±èÇýÁ¤ ( Kim Hae-Jeung ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼ºÁ¦ÀϺ´¿ø º´¸®°ú
±èÀÇÁ¤ ( Kim Yee-Jeong ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼ºÁ¦ÀϺ´¿ø º´¸®°ú
¹®º´»ê ( Moon Byoung-San ) 
ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
±è¼¼Áß ( Kim Sei-Joong ) 
ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
ÇÑÇý½Â ( Han Hye-Seung ) 
ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
ÁÖ¿µÃ¤ ( Chu Young-Chae ) 
ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
½Å¼®È¯ ( Shin Suk-Hwan ) 
ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

Abstract


Purpose: NO, a diatomic free radical, plays a diverse physiological and pathophysiological roles in the vascular, neuronal and immune systems. It is produced by nitric oxide synthase (NOS) which consists of three different isoforms. In this
study
we investigated NOS expression in 84 human breast carcinomas and its associations to other clinicopathological factors.

Methods: The immunohistochemical staining for NOS expression in 84 human breast carcinomas were performed and their medical records were reviewed retrospectively.

Results: iNOS expression in tumor cells was observed in 48.2% and eNOS expression was detected in 51.9%. iNOS expression in tumor cells has positive correlation with eNOS expression in tumor and is associated with iNOS expression in stroma
and
endothelial cells. Although iNOS expression in tumor cells has negative correlation with tumor size (P=0.047) and lymph node metastasis (P=0.002), it has no effects on 5 year overall and disease free survivals. iNOS expression in stroma also has
negative correlation with tumor size (P=0.016) and nuclear grade (P=0.025). No significant correlation between eNOS expression and clinicopathological factors was observed but eNOS expression in tumor cells contributed to worse 5 year overall
survivals
(92.1% vs 77.0%) in marginal significance (P=0.053).

Conclusion: These data suggest that iNOS expression in tumor may have an inhibitory effect in tumor growth and lymph node metastasis. These results may be further investigated.

Å°¿öµå

Nitric oxide synthase (NOS); À¯¹æ¾Ï; ¸²ÇÁÀý ÀüÀÌ; Nitric oxide synthase (NOS); Breast Cancer; Lymph Node Metastasis;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS